INSIGHTS ON EMERGING CAR T THERAPIES

Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...

Chimeric antigen receptor(CAR)-engineered natural killer (NK) cells designed with a CD28 costimulatory domain have superior anti-tumor efficacy and long-term cytotoxicity, research indicates.

Researchers from the Centre de Recherche Saint-Antoine (CRSA) at Sorbonne Université in France investigated the impact of early recovery of mucosal-associated invariant T (MAIT) cells and...

Results of a single-site analysis suggest that despite emerging concern over the potential for secondary tumors and T-cell lymphoma following chimeric antigen receptor (CAR) T-cell infusion, such...

Preliminary data support bridging radiotherapy (BRT) as a pathway to rapid, significant cytoreduction in patients with central nervous system lymphoma (CNSL) before they undergo chimeric antigen...

Chimeric antigen receptor (CAR) T-cells aimed at glypican-2 (GPC2) could delay ocular loss in patients with metastatic retinoblastoma, according to research with human samples and mouse models.